Loading...
•
Mar 29
Hologic Q2 2025 Earnings Report
Hologic reported a net loss due to impairment charges but achieved non-GAAP EPS at the high end of guidance.
Key Takeaways
Hologic delivered Q2 2025 results that met revenue and adjusted EPS guidance, despite a GAAP net loss driven by significant intangible asset impairment charges.
Revenue came in at $1,005,300,000, slightly exceeding guidance.
GAAP EPS was a loss of $0.08 due to $220.9 million in impairment charges.
Non-GAAP EPS was $1.03, reaching the high end of guidance.
Diagnostics and skeletal health segments performed strongly, offsetting declines in breast health.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comCytology & Perinatal Revenue
CapyFin.comBlood Screening Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Hologic maintained its full-year revenue guidance but lowered its EPS expectations due to tariffs and geopolitical uncertainty.
Positive Outlook
- Full-year revenue guidance of $4.05B to $4.1B reaffirmed.
- Non-GAAP EPS for Q3 guided to $1.04–$1.07.
- Diagnostics and skeletal health units expected to remain strong.
- Adjusted ROIC remains healthy at 13.7%.
- Net leverage ratio kept low at 0.8x.
Challenges Ahead
- GAAP and non-GAAP full-year EPS guidance lowered.
- Tariff and geopolitical headwinds impacting profitability.
- Breast health revenues expected to remain under pressure.
- COVID-19 related revenues continue to decline sharply.
- GAAP margins adversely affected by impairment charges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income